Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Study of MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is ongoing, but not recruiting participants.
Study NCT01283035   Information provided by National Cancer Institute (NCI)

First Received on January 24, 2011.   Last Updated on May 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Sarcoma
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Additional conditions recognized in this trial
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Sarcoma
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Interventions listed in this trial
Akt inhibitor MK2206
laboratory biomarker analysis
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services